Marinus Pharmaceuticals (NASDAQ: MRNS) of Radnor said Monday it entered into a five-year development contract with the Biomedical Advanced Research and Development Authority (BARDA) to support the development of IV ganaxolone for the treatment of refractory status epilepticus — a condition that can result from exposure to chemical weapons.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,